Aducanumab and UsAgainstAlzheimer’s

Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. UsAgainstAlzheimer’s (UsA2) has urged the U.S. Food and Drug Administration to approve aducanumab.

Read More

UsAgainstAlzheimer’s Survey Shows Alzheimer’s Patients Value a New Therapy that Slows Progression of Symptoms

New survey results from UsAgainstAlzheimer’s A-LIST shows that patients want FDA to weigh willingness of people with MCI/mild Alzheimer’s to take a disease-modifying therapy

Read More

Paid Leave Alliance for Dementia Caregivers Applauds American Rescue Plan but Urges Action on Paid Leave Support for Caregivers

The Paid Leave Alliance for Dementia Caregivers commends the Biden-Harris for making support for working families a top priority in its $1.9 trillion COVID-19 economic relief proposal but urges the administration to clarify how the proposal's paid leave expansions will cover Americans who care for older adults.

Read the Full Statement

UsAgainstAlzheimer’s Commends Apple and Biogen for New Research on Monitoring Brain Health

UsAgainstAlzheimer’s commends Apple and Biogen for their investment in brain health research and working towards creating innovative technologies that would allow consumers to be more aware and in control of their brain health.

Read Biogen's Full Statement

UsAgainstAlzheimer’s Applauds $300 Million Increase for Alzheimer’s Research at NIH

This $300 million increase will continue breakthrough NIH research and help our nation reach the goal of effective treatments, prevention and a cure for Alzheimer's disease. Read UsA2's statement on the 2021 Congressional spending bill and what it means for the millions of patients, caregivers and families urgently in need of breakthrough Alzheimer's innovations.

Read More

ICYMI: Capitol Hill Briefing on Preventing Alzheimer's & Dementia

The latest developing science increasingly tells us that Alzheimer’s disease and dementia may often be preventable. Tune in to this Capitol Hill briefing for policymakers, advocates, and the general public to hear Laura Gitlin, Dr. Lisa Barnes, and actress and advocate Mandy Moore speak about the possibility of prevention and the importance of lifestyle and behavior modifications to increase brain health across the lifespan.

Watch the Briefing

Aducanumab and UsAgainstAlzheimer’s

UsAgainstAlzheimer’s Survey Shows Alzheimer’s Patients Value a New Therapy that Slows Progression of Symptoms

Paid Leave Alliance for Dementia Caregivers Applauds American Rescue Plan but Urges Action on Paid Leave Support for Caregivers of Older Adults

UsAgainstAlzheimer’s Commends Apple and Biogen for New Research on Monitoring Brain Health

UsAgainstAlzheimer’s Applauds $300 Million Increase

ICYMI: Capitol Hill Briefing on Preventing Alzheimer's & Dementia

  • A Letter from Our Chairman

    UsAgainstAlzheimer’s Brain Health Partnership has issued a Call to Action white paper outlining recommendations for building a better system of care to promote brain health and fight back against Alzheimer’s.

Read the Letter

We Are Committed to Stopping Alzheimer's.

  • Blog Post
    Thumbnail

    A Case for FDA Approval: Biogen’s Aducanumab - First-Ever Drug to Slow Progression of Alzheimer’s

    Time kills deals, as the saying goes. And the biggest deal on the Alzheimer’s front—in terms of improving cognition in the early stages of the disease—is Biogen’s new drug aducanumab

    Read more
  • Blog Post
    Thumbnail

    The Biden Administration Can Reinvigorate the National Fight Against Alzheimer’s

    The Biden-Harris administration should renew and recommit to the national goal of preventing and effectively treating Alzheimer’s disease by 2025. This goal was set 10 years ago this month. It

    Read more
  • Blog Post
    Thumbnail

    COVID-19 and Dementia: What People Have Learned about Themselves

    The Alzheimer’s community has experienced enormous hardship and heartache since the COVID-19 pandemic started in March. Dementia caregivers are dealing with ongoing stress and people with Alzheimer’s report more rapid

    Read more

The Pulse of the Community: Coronavirus Impacts on Alzheimer's Community

The A-LIST transforms the stories of more than 7,500 people living with Alzheimer’s or other dementias into evidence-based insights by providing unique, rapid-response, self-reported data through virtual surveys on what matters most on a wide range of Alzheimer’s-related topics. The A-LIST offers a powerful and validating voice for those living with Alzheimer’s and those caring for them, and a pathway to help expand treatments and accelerate toward a cure.

Read More